(3S,3'S,4'R,6'S,8'R,8'aR)-5-(4-hydroxybut-1-ynyl)-6'-[4-(2-hydroxyethoxy)phenyl]-1',2-dioxo-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-8'-carboxylic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (3S,3'S,4'R,6'S,8'R,8'aR)-5-(4-hydroxybut-1-ynyl)-6'-[4-(2-hydroxyethoxy)phenyl]-1',2-dioxo-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-8'-carboxylic acid
• 化学式: C₃₉H₃₄N₂O₈
• 分子量: 658.7
• InChiKey: ZCSGZQQNXICREI-LHLFRUFXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  49
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  146
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
  申请人：Moon Randall T.

  公开号：US20120046242A1

  公开（公告）日：2012-02-23

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.